Sun Pharma Partners with Takeda for Novel Gastrointestinal Drug in India

Sun Pharmaceutical Industries has partnered with Takeda Pharmaceutical Company to commercialize the novel gastrointestinal drug Vonoprazan in India. This agreement will bring an innovative treatment option for reflux esophagitis and acid peptic disorders to the Indian market. Vonoprazan was approved by the US FDA in November 2023.

In a significant development for gastrointestinal health in India, Sun Pharmaceutical Industries announced on Friday its licensing agreement with Takeda Pharmaceutical Company. The deal will commercialize Vonoprazan, a novel drug, within the country.

Under the non-exclusive pact, Sun Pharma will offer Vonoprazan tablets in 10 and 20 mg strengths. This drug is an orally active potassium competitive acid blocker (PCAB) that targets conditions like reflux esophagitis and acid peptic disorders.

Sun Pharma's CEO for India Business, Kirti Ganorkar, expressed enthusiasm about the partnership, highlighting the company's leadership in gastroenterology. He stressed the importance of offering a new treatment option to patients and healthcare practitioners. The approval of Vonoprazan by the US FDA in November 2023 further solidifies its credibility as a reliable treatment for various gastrointestinal conditions.

The company's shares saw a modest increase of 0.69 per cent, trading at Rs 1,480.55 apiece on the BSE.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)